Expert Interview
A Second View: Discussing the Recent FDA Approval of Amneal Pharmaceuticals' Self-Administered Drug, Brekiya, for the Treatment of Acute Cases of Migraine and Severe Cluster Headaches in Adults
Ticker(s): AMRXInstitution: Dartmouth-Hitchcock Medical Center
- Clinical Neurologist. Director of the Dartmouth Headache Center, and Professor of Neurology at Geisel School of Medicine, Dartmouth.
- Treats~150 migraine patients per month.
- Previously investigator in the rimegepant Phase 2 trial when it was owned by BMS. and has published over 330 peer-reviewed manuscripts, editorials, and books.
Where are the unmet needs in acute migraine and cluster headache treatment?
Added By: nick_adminWhat is your initial impression of Brekiya (dihydroergotamine mesylate autoinjector) following FDA approval?
Added By: nick_adminWhere in the treatment algorithm do you see Brekiya being used?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
